Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation

Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group

(2014) Noelia Purroy et al.   BRITISH JOURNAL OF HAEMATOLOGY

Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era

(2014) Naokuni Uike et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12

(2014) Michael Crump et al.   JOURNAL OF CLINICAL ONCOLOGY

Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial

(2014) Kirit M Ardeshna et al.   LANCET ONCOLOGY

Outcomes after90Yttrium-ibritumomab tiuxetan-BEAM in diffuse large B-cell lymphoma: a meta-analysis

(2014) Sophie Auger-Quittet et al.   Cancer Medicine

KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis

(2013) Laurence Beck et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma

(2013) M. J. Matasar et al.   BLOOD

Activation of the STAT3 Signaling Pathway Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP

(2013) Xin Huang et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of AKT2 Enhances Sensitivity to Gemcitabine via Regulating PUMA and NF-κB Signaling Pathway in Human Pancreatic Ductal Adenocarcinoma

(2012) Dong Chen et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Prenyltransferases Regulate CD20 Protein Levels and Influence Anti-CD20 Monoclonal Antibody-mediated Activation of Complement-dependent Cytotoxicity

(2012) Magdalena Winiarska et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity

(2012) Henrik E Mei et al.   ARTHRITIS RESEARCH & THERAPY

Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma

(2011) Bojie Dai et al.   Nature Communications

Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity

(2010) J. Bil et al.   BLOOD

ESHAP Versus Rituximab-ESHAP in Frail Patients With Refractory Diffuse Large B-Cell Lymphoma

(2010) Agustin Avilés et al.   Clinical Lymphoma Myeloma & Leukemia

Lymphoma Recurrence 5 Years or Later Following Diffuse Large B-Cell Lymphoma: Clinical Characteristics and Outcome

(2010) Jean-François Larouche et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells

(2010) R Shimizu et al.   LEUKEMIA

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

(2010) John H. Stone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antigenic Modulation and Rituximab Resistance

(2010) Ronald P. Taylor et al.   SEMINARS IN HEMATOLOGY

Anti-CD20 monoclonal antibodies: historical and future perspectives

(2009) S. H. Lim et al.   HAEMATOLOGICA

The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis

(2009) Hisakazu Nishimori et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY